期刊
EBIOMEDICINE
卷 2, 期 4, 页码 294-305出版社
ELSEVIER
DOI: 10.1016/j.ebiom.2015.03.009
关键词
Mitochondrial complex I activity; Cellular energetics; Alzheimer's disease; AMPK; Amyloid beta; Hyperphosphorylated tau; GSK3beta; Axonal trafficking; Animal models of familial AD
资金
- NIEHS [R01ES020715]
- ADDF [291204]
- BrightFocus [A2011084]
- Mayo Clinic ADRC
- NCATS [UL1 TR000135]
- NIH [AG025500, P30 AG10129]
Development of therapeutic strategies to prevent Alzheimer's disease (AD) is of great importance. We show that mild inhibition of mitochondrial complex I with small molecule CP2 reduces levels of amyloid beta and phospho-Tau and averts cognitive decline in three animal models of familial AD. Low-mass molecular dynamics simulations and biochemical studies confirmed that CP2 competes with flavin mononucleotide for binding to the redox center of complex I leading to elevated AMP/ATP ratio and activation of AMP-activated protein kinase in neurons and mouse brain without inducing oxidative damage or inflammation. Furthermore, modulation of complex I activity augmented mitochondrial bioenergetics increasing coupling efficiency of respiratory chain and neuronal resistance to stress. Concomitant reduction of glycogen synthase kinase 3 beta activity and restoration of axonal trafficking resulted in elevated levels of neurotrophic factors and synaptic proteins in adult AD mice. Our results suggest that metabolic reprogramming induced by modulation of mitochondrial complex I activity represents promising therapeutic strategy for AD. (C) 2015 The Authors. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据